Category Archives: Cardiomyopathies

A new PET radiotracer has shown promise for its ability to image fibroblast activity following a heart attack, say researchers in Germany. The team has gained greater insight into the recovery process of hearts that have undergone myocardial infarction, with the use of 68Ga-FAPI-04 PET, a radiopharmaceutical that can target fibroblast activation prior to it causing permanent damage. Its application enables clinicians to identify a window of time in which cardiac fibrosis, which can contribute to heart failure, can be prevented and the course of the disease altered Continue reading →

Global Cell Culture Protein Surface Coating Market: Snapshot The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions. These cells are used to develop model systems for study and research of cellular structures as well as for drug discovery and genetic engineering. Continue reading →

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Inc.(Nasdaq: CYTK) today announced that new results were presented at the 30th International Symposium on ALS/MND in Perth, Australia, including additional analyses from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints in ALS), the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS). Among the post-hoc analyses presented were results of subgroup analyses describing the effect of reldesemtiv with and without use of Radicava (edaravone) and/or Rilutek (riluzole) and the interaction between quality of life and depression in the placebo group. Continue reading →

Lonza and DiNAQOR AG, a global gene therapy platform company, announced a strategic collaboration to advance DiNAQOR's preclinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure. Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies. Continue reading →

BASEL,Switzerland and PFFFIKON,Switzerland, Nov. Continue reading →

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on October 31, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future Continue reading →

Global Cell Culture Protein Surface Coating Market: Snapshot The global market for cell culture protein surface coatings is slated to expand at a highly promising pace in the next few years, thanks to the vast rise in investments by governments and market players in stem cell research and development activities. Cell culturing is a method used for growing artificial living cells outside the natural environment, under controlled physical conditions Continue reading →

The TMR report projects the globalcardiac surgery instruments marketto register an impressive CAGR of 5.9% from 2017 to 2022. Continue reading →

Faster Progressing Patients Who Received Reldesemtiv in the TrialDemonstrated Statistically Significant Differences in the Decline in ALSFRS-R Total Score SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints in ALS), the Phase 2 clinical trial ofreldesemtivin patients with amyotrophic lateral sclerosis (ALS). Continue reading →

Heart related disorders are mostly inherited from parents to their children. Cardiovascular genomic diagnostics testing helps in detecting these inherited diseases such as cardiac channelopathies and congenital heart diseases. Besides cardiovascular genomic diagnostics can also be helpful for family members who have risks of developing heart problems Continue reading →